WO2004080272A3 - Utilisation des genes leprotl1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal - Google Patents

Utilisation des genes leprotl1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal Download PDF

Info

Publication number
WO2004080272A3
WO2004080272A3 PCT/FR2004/000572 FR2004000572W WO2004080272A3 WO 2004080272 A3 WO2004080272 A3 WO 2004080272A3 FR 2004000572 W FR2004000572 W FR 2004000572W WO 2004080272 A3 WO2004080272 A3 WO 2004080272A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
rgrp
leprotl1
diabetes
loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2004/000572
Other languages
English (en)
Other versions
WO2004080272A2 (fr
Inventor
Bernard Bailleul
Yves Rouille
Karin Seron
Sandrine Belouzard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Original Assignee
Centre National de la Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique filed Critical Centre National de la Recherche Scientifique
Priority to CA002518761A priority Critical patent/CA2518761A1/fr
Priority to EP04718992A priority patent/EP1601973A2/fr
Publication of WO2004080272A2 publication Critical patent/WO2004080272A2/fr
Publication of WO2004080272A3 publication Critical patent/WO2004080272A3/fr
Priority to US11/221,275 priority patent/US20060068429A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne une méthode d'identification de composés actifs sur la perte ou la prise de poids ou le diabète chez un sujet humain ou animal, caractérisé en ce que l'on mesure l'effet dudit composé sur (a) l'expression de l'un au moins des gènes LEPROTL1 et OB­ RGRP ou partie de ceux-ci, et/ou (b) le transport intracellulaire jusqu'à la membrane cellulaire, et/ou (c) la présence au niveau de la membrane cellulaire, et/ou (d) l'internalisation depuis la membrane, des protéines codées par l'un au moins desdits gènes ou partie de ceux-ci.
PCT/FR2004/000572 2003-03-10 2004-03-10 Utilisation des genes leprotl1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal Ceased WO2004080272A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002518761A CA2518761A1 (fr) 2003-03-10 2004-03-10 Utilisation des genes leprotl1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal
EP04718992A EP1601973A2 (fr) 2003-03-10 2004-03-10 Utilisation des genes leprotl1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d un sujet humain ou animal
US11/221,275 US20060068429A1 (en) 2003-03-10 2005-09-07 LEPROTL1 and OB-RGRP genes for screening compounds that act on the gain or loss of weight or on diabetes in a human or animal subject

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR03/02931 2003-03-10
FR0302931A FR2852397B1 (fr) 2003-03-10 2003-03-10 Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/221,275 Continuation US20060068429A1 (en) 2003-03-10 2005-09-07 LEPROTL1 and OB-RGRP genes for screening compounds that act on the gain or loss of weight or on diabetes in a human or animal subject

Publications (2)

Publication Number Publication Date
WO2004080272A2 WO2004080272A2 (fr) 2004-09-23
WO2004080272A3 true WO2004080272A3 (fr) 2004-11-04

Family

ID=32893169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2004/000572 Ceased WO2004080272A2 (fr) 2003-03-10 2004-03-10 Utilisation des genes leprotl1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal

Country Status (5)

Country Link
US (1) US20060068429A1 (fr)
EP (1) EP1601973A2 (fr)
CA (1) CA2518761A1 (fr)
FR (1) FR2852397B1 (fr)
WO (1) WO2004080272A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070050237A1 (en) * 2005-08-30 2007-03-01 Microsoft Corporation Visual designer for multi-dimensional business logic
TWI824372B (zh) 2015-10-12 2023-12-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
MA45801B1 (fr) 2016-11-08 2021-11-30 Regeneron Pharma Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine
SG11202005146VA (en) 2017-12-18 2020-06-29 Regeneron Pharma Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
SMT202500283T1 (it) 2018-04-06 2025-09-12 Regeneron Pharma Un anticorpo agonista del recettore della leptina da utilizzare per aumentare la massa ossea in un soggetto affetto da disfunzione metabolica o ipoleptinemia
WO2024259474A1 (fr) * 2023-06-19 2024-12-26 Perron Institute for Neurological and Translational Science Limited Traitement de maladies malignes basé sur le transfert de séquence d'acide nucléique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAILLEUL B ET AL: "THE LEPTIN RECEPTOR PROMOTER CONTROLS EXPRESSION OF A SECOND DISTINCT PROTEIN", 1997, NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, VOL. 25, NR. 14, PAGE(S) 2752-2758, ISSN: 0305-1048, XP002050420 *
HUANG Y ET AL: "Cloning and characterization of a novel human leptin receptor overlapping transcript-like 1 gene (LEPROTL1)", 2001, BIOCHIMICA ET BIOPHYSICA ACTA. GENE STRUCTURE AND EXPRESSION, ELSEVIER, AMSTERDAM, NL, VOL. 1517, NR. 2, PAGE(S) 327-331, ISSN: 0167-4781, XP004248823 *
SERON K ET AL: "OB-RGRP AND LEPROTL1 DEFINE A NEW FAMILY OF LIPID RAFT-ASSOCIATED TETRASPANNING MEMBRANE PROTEINS LOCALIZED AT THE TGN AND/OR ENDOSOMES", 2001, BIOLOGY OF THE CELL, VOL. 93, PAGE 227, 2001, XP001154434 *

Also Published As

Publication number Publication date
FR2852397A1 (fr) 2004-09-17
FR2852397B1 (fr) 2005-04-29
WO2004080272A2 (fr) 2004-09-23
CA2518761A1 (fr) 2004-09-23
EP1601973A2 (fr) 2005-12-07
US20060068429A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
WO2008064778A3 (fr) Combinaisons d'agents actifs insecticides (formononétine + insecticides)
WO2007027777A3 (fr) Sequences nucleotidiques codant des proteines insecticides
WO2006071107A8 (fr) Composition d'acariens, son utilisation, procede pour developper un acarien predateur des phytoseiides, systeme de developpement pour developper ledit acarien predateur des phytoseiides et procedes de controle biologique des ravageurs sur une recolte
CR20130637A (es) Combinaciones de productos activos con propiedades namaticidas e insecticidas, basadas en compuestos de trifluorbutenilo
WO2004060052A3 (fr) Souris transgeniques exprimant le cd20 et/ou le cd16 humain(s)
EA200702312A1 (ru) Пестицидные комбинации биологически активных веществ
AP2006003568A0 (en) 2-cyanobenzenesulfonamides for combating animal pests.
MX2007000392A (es) Derivados de 2-pirrolidona sustituida como fungicidas e insecticidas.
ATE508634T1 (de) Wirkstoffkombinationen mit nematiziden, insektiziden und fungiziden eigenschaften basierend auf trifluorbutenyl-verbindungen
WO2008037375A3 (fr) Concentrés de suspension
WO2004096985A3 (fr) Procedes d'evaluation de la diversite biologique
DE60230651D1 (de) Iminobenzoxazine, iminobenzothiazine and iminoquinazoline zur bekämpfung von wirbellosen schädlingen
WO2007054160A3 (fr) Procede de cryoconservation de sang humain preservant la fonction des monocytes et des lymphocytes
BRPI0807012A2 (pt) Uso de inseticidas, método de reduzir ou evitar o efeito fitotóxico de fungicidas, e, agente.
WO2009048752A3 (fr) Dérivés azinyliques substitués insecticides
WO2009012909A3 (fr) Combinaisons de principes actifs insecticides (genistéine + insecticide)
WO2004006854A3 (fr) Procede d'identification d'agents biologiquement actifs
ATE259379T1 (de) Fluoresceinisothiocyanat-(fitc)-sinistrin, seine herstellung und verwendung
EP1376359A3 (fr) Traitement des informations de configuration pour dispositifs de stockage réseau
CU23309B7 (es) Compuestos anã logos de astrobilurinas y su uso como acaricida e insecticida
DE602004021567D1 (de) Antikörper gegen tumorspezifisches antigen als ziel
WO2003007878A3 (fr) Agents antifongiques de derives de sordarine
ITRM20030127A0 (it) Composizione alimentare, pasta alimentare funzionale da essa ottenutae procedimento per la sua preparazione.
NO20064729L (no) Parasitticidale midler
BR0310126B1 (pt) mÉtodo de conservaÇço de produto de madeira, e produto de madeira tendo propriedades inseticidas/acaricidas.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11221275

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004718992

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2518761

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2004718992

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11221275

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2004718992

Country of ref document: EP